Expansion to 12 million vials per year
We are building a brand-new fully automated production line.
The unique formula
BioConnection offers young and innovative biopharmaceutical companies access to our state-of-the-art-GMP manufacturing facility and a broad range of support services. We are a contract services and manufacturing organization for the development and manufacture (Filling and Freeze drying) of injectable (bio)pharmaceutical products. The Netherlands are located centrally in Europe and from our proprietary site in Oss we supply both clinical as commercial products to our worldwide customers (FDA/EMA). Besides the central location, The Netherlands are also well known for their professional flexibility, organizational savvy and command of foreign languages. Besides our own EMA/FDA approved facility we have access to various facilities across Europe to enable an unmatched flexibility in solutions, capacity and capability. The cornerstones of our CMC services are: Drug Product development, Fill and Finish, Freeze drying and Finished Product services.
Any specific needs?
Challenge us with your question by filling in this form immediately!
Our building blocks to fullfill your needs. You can tailor our services to your specific needs.
GMP manufacturing facility
- Aseptic filling
- Freeze drying
- Terminal sterilization
- Batch certification
- EMA and US-FDA track record
- Automated fill
- Manual fill, labelling and packaging
- Batch volume: 2 – 50L
- Freeze-drier: Shelf surface 1 x 3 m2
- Cell based therapy
- Flexible GMP cleanroom setup
‘One of the very best experiences of tech transfer, development, scale-up and manufacture’
In early 2016, we at Verona Pharma were looking for a CMO to support the manufacture of clinical trial batches of our lead product RPL554 (ensifentrine), a first-in-class inhaled agent under development for the treatment of respiratory diseases with significant unmet medical needs such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis.
BioConnection announces that Lava Therapeutics (LAVA), a biotechnology company creating and developing next-generation γδ T cell engaging bispecific antibodies for the treatment of cancer, has selected BioConnection for GMP DP manufacturing. LAVA and BioConnection now...
Oss, The Netherlands, March 18, 2020. BioConnection has taken precautions related to the global outbreak of the Covid-19 virus. To start with; we are currently in full operation and running on-schedule with regard to our planned productions. Our production department...
Oss, The Netherlands, April 8, 2019. BioConnection will invest €12 million in a second, commercial scale, manufacturing line to keep up with the growing customer demand and to ensure its future company growth. BioConnection, Contract Manufacturing Organization (CMO),...